Back
Oxidised phospholipids as biomarkers in human disease.
Journal article

Oxidised phospholipids as biomarkers in human disease.

  • Philippova M Department of Biomedicine, Laboratory for Signal Transduction, University Hospital Basel, University of Basel, Switzerland.
  • Resink T Department of Biomedicine, Laboratory for Signal Transduction, University Hospital Basel, University of Basel, Switzerland.
  • Erne P Hirslanden Klinik St. Anna, Luzern, Switzerland.
  • Bochkov V Institute of Pharmaceutical Sciences, Pharmaceutical Chemistry, Karl-Franzens-University Graz, Austria.
Show more…
  • 2014-12-25
Published in:
  • Swiss medical weekly. - 2014
Animals
Apolipoprotein A-II
Atherosclerosis
Biomarkers
Chronic Disease
Coronary Artery Disease
Coronary Restenosis
Diabetes Mellitus, Type 2
Enzyme-Linked Immunosorbent Assay
Glycerophospholipids
Humans
Lipoproteins, LDL
Metabolic Syndrome
Nervous System Diseases
Oxidative Stress
Renal Insufficiency
Spectrometry, Mass, Electrospray Ionization
English Oxidised phospholipids (OxPLs) are generated from (poly)unsaturated diacyl- and alk(en)ylacyl glycerophospholipids under conditions of oxidative stress. OxPLs exert a wide variety of biological effects on diverse cell types in vitro and in vivo and are thought to play a role in the development of several chronic diseases including atherosclerosis, a classical lipid-associated and inflammatory disorder. OxPLs are recognised as culprit molecular components responsible for the pathophysiological actions of oxidised low-density lipoproteins. There is growing interest in the potential use of OxPLs as biomarkers of human pathologies. Here we offer a brief overview of current detection methods and knowledge on relationships between levels of circulating OxPLs and disease progression, with particular emphasis on cardiovascular disease.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/110898
Statistics
Document views: 9 File downloads: